Kevin Judice, DICE Therapeutics CEO

Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

DICE Ther­a­peu­tics is now mov­ing for­ward on the next stage of clin­i­cal de­vel­op­ment for its IL-17 can­di­date, on the heels of tout­ing a Phase I …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.